RxDoctor Payments Data

Thomas Phiambolis, MD

Cardiovascular Disease · Wynnewood, PANPI 1144225905

Payments from drug & device makers

$57,855in general payments, 2019–2025

Across 170 payments — averaging $340.32 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Amarin Pharma, Inc.$22K
  • Heartflow, Inc.$13K
  • Sanofi-aventis U.S. LLC$11K
  • Amgen$8K
  • Regeneron Healthcare Solutions, Inc.$1K
  • Novartis$571
  • plus $732 from 11 others

What the payments were for

  • Consulting fees$3,0768%
  • Speaking & faculty fees$30,60881%
  • Food & beverage$3,98411%
  • Education$970%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$57,855 in reported general payments places this provider in the 90th percentile of 1,250 cardiovascular disease providers in Pennsylvania.

See all cardiovascular disease providers in Pennsylvania

Medicare billing

Part B allowed, 2024
$72,010
Medicare patients
390
Services billed
865

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Repatha SureclickEvolocumab169$237,753
Praluent PenAlirocumab60$72,718
XareltoRivaroxaban40$51,269
EliquisApixaban38$50,858
VascepaIcosapent Ethyl41$34,429
Ezetimibe300$9,271
EntrestoSacubitril/Valsartan12$4,286
Rosuvastatin Calcium321$3,790
Atorvastatin Calcium190$2,279
Metoprolol Succinate115$2,125
Amlodipine Besylate72$844
Omega-3 Acid Ethyl Esters14$738
Losartan Potassium69$735
ClopidogrelClopidogrel Bisulfate40$719
Olmesartan Medoxomil18$586

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonXarelto$93$51,26940 claims
PfizerEliquis$54$50,85838 claims
NovartisEntresto$571$4,28612 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 1,250 cardiovascular disease providers in Pennsylvania.

Other cardiovascular disease in Wynnewood

See the full list for Pennsylvania

Where these figures come from

Is this you, or does something look wrong? →